Clinical Trial

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2025, and recommended dose of VG2025 for Phase II trials.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-07-25; most recent amendment 2025-03-26.
Status change: Not Yet Recruiting → Recruiting 2022-10-12
Trial Details
NCT Number NCT05477849
Lead Sponsor Shanghai Virogin Biotech Co., Ltd.
Conditions Advanced Malignant Solid Tumor
Enrollment 30 participants
Start Date 2022-08-23
Primary Completion 2025-10-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-01